SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBridgepoint Regulatory News (BPT)

Share Price Information for Bridgepoint (BPT)

Share Price is delayed by 15 minutes
Get Live Data
244.40    5.60 (2.35%)
Bid:
244.60
Ask:
245.00
Spread: 0.40 (0.164%)
Market Cap: £2.14b
BPT Live PriceLast checked at - London Stock Exchange

Intraday Bridgepoint Share Chart

Trading Statement

16 Nov 2022 07:00

RNS Number : 5252G
Bridgepoint Group plc
16 November 2022
 

Bridgepoint Group plc

("Bridgepoint" or the "Company", and together with its subsidiaries the "Group")

 

 

Trading statement: Resilient progress across the Group and guidance for FY 2022 unchanged

 

 

Despite more challenging macro conditions, Bridgepoint is pleased to report that it remains on track against key targets for 2022.

 

Capital raising

 

Capital raising for Bridgepoint's equity and credit businesses continues to make progress, reflecting the attractions of the well-balanced portfolios Bridgepoint constructs which have a good track record of delivering attractive returns from growth investment niches through cycles. In particular:

 

Bridgepoint Europe VII is on track to complete its fund raise in H1 2023 with the Fund expected to hold its formal second closing in Q1 2023 with some investors wishing to draw capital from their 2023 annual allocations

The Fund continues to enjoy strong interest from investors. As noted previously, the broader fund raise market is affected by the well documented denominator effect with falling quoted portfolio valuations impacting portfolio weightings. This is extending most current fund raising processes

Both Bridgepoint Credit and Bridgepoint Growth fund raising programmes are also making good progress

 

Portfolio valuation

 

Following its September portfolio and valuation review, the Group can confirm that its investment portfolios are trading largely in line with expectations set at the start of the year despite current macro volatility:

 

Bridgepoint's equity portfolios comprise mainly high margin, cash generative, growth companies (for example, 29% EBITDA/revenue average margin in BE VI)

Equity portfolios have currency hedging covering some 78% of non-Euro exposures

Rate hedging is in place for 69% of equity fund interest costs

Funds have limited exposure to the UK (comprising only 2.5% of BE VI assets, for example)

Bridgepoint funds also have limited exposure to assets driven by discretionary spending

Portfolio companies have been impacted by rising energy costs, but Bridgepoint portfolios, as a whole, do not comprise businesses with high energy use and energy costs represent on average less than 2% of portfolio company revenues

 

These attributes were reflected in Q3 valuations which are in line with expectations, with underlying profit growth within portfolios compensating for the fall in valuation multiples across different sectors.

 

Current trading and outlook

 

The Group also reports that:

 

Whilst exits across the market have been more challenging during the second half of the year, it remains on track to hit budgeted realisations for 2022 with two major exits signed in Q3 at valuations ahead of expectations

Capital commitments in all funds are in line with expectations with BE VII having now committed some 10% of fund capital since the start of the investment period in mid-May 2022

Bridgepoint Credit continues to perform well against its targets for 2022

Portfolio exit plans for 2023 are unchanged but execution will be dependent on market conditions

A number of strategic projects remain under review. However, the Group currently remains cautious in evaluating acquisitions as valuation metrics re-calibrate

 

In the context of the above, Bridgepoint's financial guidance for 2022 remains unchanged and the Group's outlook for 2023 financial performance remains positive.

 

 

ENQUIRIES

 

Bridgepoint

 

Analysts and investors

Adam Key

adam.key@bridgepoint.eu

+44 7833 748010

 

Media

James Murray

james.murray@bridgepoint.eu

+44 20 7034 3500

 

Finsbury Glover Hering (Public Relations Adviser to Bridgepoint)

 

Charles O'Brien / +44 20 7251 3801 / +44 7825 043 656

Anjali Unnikrishnan / +44 20 7251 3801 / +44 7826 534 233

bridgepoint@fgsglobal.com 

 

 

Legal Entity Identifier (LEI): 213800KFNMVI8PDZX472

 

Forward looking statements

 

This announcement may include forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time made, the beliefs, intentions and current targets/aims of Bridgepoint Group plc. Forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this announcement are based upon various assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Forward-looking statements are not guarantees of future performance and such risks, uncertainties, contingencies and other important factors could cause the actual outcomes and the results of operations, financial condition and liquidity of the Company, its subsidiary undertakings or the industry to differ materially from those results expressed or implied in this announcement by such forward-looking statements. No representation or warranty, express or implied, is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved. Undue influence should not be given to, and no reliance should be placed on, any forward-looking statement. No statement in this announcement is intended to be nor may be construed as a profit forecast. Neither the Company, nor any of its subsidiaries nor any of their affiliates, nor any of its or their officers, employees, agents or advisers, undertake to publicly update or revise any such forward-looking statement, except to the extent required by applicable law.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFETLTLELIF
Date   Source Headline
20th Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSRule 19.6(c) Confirmation
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 202611:15 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20257:00 amRNSTransaction in Own Shares
17th Dec 20253:31 pmRNSIssue of Equity and Total Voting Rights
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20254:30 pmRNSAdditional Listing
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:15 pmRNSDirector/PDMR Shareholding
17th Nov 20251:15 pmRNSDirector/PDMR Shareholding
14th Nov 20257:05 amRNSVariation of Lock-up Arrangements
14th Nov 20257:00 amRNSResults of Secondary Placing
13th Nov 20255:07 pmRNSProposed Secondary Placing of Ordinary shares
1st Sep 20257:00 amRNSTotal Voting Rights
19th Aug 20257:00 amRNSRule 19.6(c) Confirmation
5th Aug 20257:00 amRNSTransaction in Own Shares
4th Aug 20257:00 amRNSTransaction in Own Shares
1st Aug 20257:00 amRNSTransaction in Own Shares
31st Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSHalf-year Report
2nd Jun 20257:00 amRNSShare Buyback Programme
15th May 20252:45 pmRNSResult of AGM
1st May 20257:00 amRNSTotal Voting Rights
14th Apr 20257:00 amRNSDirectorate Change
2nd Apr 20252:00 pmRNSDirector/PDMR Shareholding
2nd Apr 20252:00 pmRNSDirector/PDMR Shareholding
1st Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
31st Mar 20257:00 amRNSTransaction in Own Shares
28th Mar 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.